Immunocore presented three posters about KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma at the 2024 ASCO Annual Meeting. These data showed that treatment benefit for patients with stable disease and any confirmed tumor reduction was similar to patients with partial response. Of the 127 patients treated with KIMMTRAK in the Phase 2 trial, 25% had any tumor reduction that was confirmed in at least one subsequent scan, including 6 partial responses, an overall response rate of 5%, and 20% stable disease. The clinical outcomes in the 26 patients with SD were similar to the 6 PR patients, including durable duration of tumor reduction or response, ctDNA molecular response, and overall survival. In the Phase 3 trial, KIMMTRAK-treated patients with SD who had any confirmed tumor reduction had durability of tumor reduction of 11 months, which was the same as the durability of response for patients with RECIST PR or CR.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
- Immunocore Reveals Promising Brenetafusp Trial Results
- Immunocore reports updated brenetafusp data
- Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
- Immunocore to present at the Jefferies Global Healthcare Conference
Questions or Comments about the article? Write to editor@tipranks.com